This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Richards, A. M. Search for Related Content PubMed PubMed Citation Articles by Richards, A. M.

Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin

Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction

A. Mark Richards, MD, PhD^a, Robert Doughty, MD, M. Gary Nicholls, MD^a , Stephen MacMahon, PhD, Norman Sharpe, MD, Judy Murphy, RN, Eric A. Espiner, MD^a, Christopher Frampton, PhD^a, Timothy G. Yandle, PhD^a for the Australia-New Zealand Heart Failure Group

^a Department of Medicine, Christchurch Hospital, Christchurch, New Zealand
Department of Medicine, Auckland, New Zealand
Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand
Institute for International Health, Sydney, Australia

View larger version (14K): [in a new window]   Figure 1 All-cause mortality (death) survival curves for patients with pre-randomization plasma adrenomedullin (ADM, left) and N-BNP (right) above (group A, solid line) and below (group B, dashed line) the group median value. p < 0.001.

View larger version (14K): [in a new window]   Figure 2 Event-free survival for hospital admission with CHF in patients with pre-randomization plasma adrenomedullin (ADM, left) and N-BNP (right) above (group A, solid line) and below (group B, dashed line) the group median value. **p < 0.01. p < 0.001.

View larger version (18K): [in a new window]   Figure 3 Event-free survival for hospital admission with heart failure in patients with below-median adrenomedullin (ADM, left) or N-BNP (right) levels receiving placebo (Bp, solid thin line) or carvedilol (Bc, dotted line) and in those with above-median peptide levels receiving placebo (Ap, solid thick line) or carvedilol (Ac, dashed line). p < 0.001. ns = not significant.